Cholesterol drug may calm inflammation after heart attack
NCT ID NCT03515304
First seen Dec 16, 2025 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This study tested whether evolocumab (Repatha), a drug that lowers LDL cholesterol, can reduce inflammation and improve heart function in people who recently had a mild heart attack (NSTEMI). Sixty participants received either evolocumab or a placebo within 24 hours of admission. The main goals were to measure changes in cholesterol levels and inflammation in the heart using PET scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Steven Paul Schulman
Baltimore, Maryland, 21136, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Evolocumab (Repatha), a drug that lowers LDL cholesterol
What this could lead to
If successful, this could show that adding evolocumab right after a heart attack reduces inflammation and improves heart recovery.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply broadly. The drug is already approved for cholesterol lowering, but its benefit in acute heart attack settings is unproven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.